BARDA seeks to advance investigational BDBV vaccine candidates using the VSV platform, including manufacturing process development and production of up to 10,000 doses of Phase 1 clinical trial material. The effort also includes a Phase 1 safety and immunogenicity trial, with options for up to 100,000 additional doses. The goal is to produce cGMP material and meet regulatory requirements for a clinical trial addressing the ongoing 2026 BDBV outbreak. No budget amount is specified. The location for performance of services is not mentioned.